GlassScriptPhysician profile
Sally Chun
NPI 1912588187
$5,817.44
in general payments reported to CMS, 2019-2025
23 companies · $1,510 in 2025
The $1,510 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $320 · 2022: $2,037 · 2023: $1,132 · 2024: $818 · 2025: $1,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,104 · Education: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,103.65 |
| Education | $356.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,057.87 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,039.02 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $769.12 | 2021-2025 | |
| Incyte Corporation | $524.12 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $479.97 | 2022-2024 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $252.72 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $252.04 | 2021-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $246.16 | 2025 | |
| Arcutis Biotherapeutics, INC. | $218.42 | 2024-2025 | Zoryve |
| Almirall LLC | $122.07 | 2022 | |
| Galderma Laboratories, L.P. | $110.88 | 2022-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $98.00 | 2023-2025 | Jublia, Arazlo, Cabtreo |
| Lilly USA, LLC | $94.37 | 2021-2025 | Taltz, Ebglyss |
| Biofrontera INC. | $80.87 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Ucb, INC. | $79.94 | 2025 | Bimzelx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $76.67 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $68.63 | 2022-2024 | Vtama |
| Organon LLC | $54.84 | 2025 | Vtama |
| Janssen Biotech, INC. | $50.54 | 2025 | Tremfya |
| Revance Therapeutics, INC. | $47.67 | 2025 | Daxxify |
| Pfizer INC. | $44.19 | 2025 | |
| Journey Medical Corporation | $33.01 | 2022 | |
| Mayne Pharma Commercial LLC | $16.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Chun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.